PRAMIPEXOLE CLINICAL TRIAL RESULTS IN PARKINSON'S DISEASE

20th May 2014 - New research

Barone, Y.Mizuno, O.Rascol, M.Busse, C.Debieuvre, M.Fraessdorf, W.Poewe
European Journal of Neurology [2014] 21 (5) : 736-743 (R.A.Hauser, A.H.Schapira, P.

Barone,Complete abstract : http://www.ncbi.nlm.nih.gov/pubmed/24834511

The long term safety and efficacy of pramipexole was assessed as an extended-release oral

formulation and immediate release formulation in early or advanced Parkinson's Disease.

Pramipexole, which is marketed as Mirapex, Mirapexin, and Sifrol, is a dopamine agonist.

For more information go to Pramipexole : http://www.rxlist.com/mirapex-drug.htm

In those people with early Parkinson's Disease the reported side

effects were somnolence (15%), peripheral edema (11%) and back

pain (10%). The scores on the Parkinson's Disease symptom score

(UPDRS) after over 2 years were down by 6.6 when using extended

release pramipexole and 6.3 when using immediate release

pramipexole. In those people with advanced Parkinson's Disease the

reported side effects were dyskinesia (27%), somnolence (13%),

and impulse control disorders (1%). The scores on the Parkinson's

Disease symptom score (UPDRS) after over 2 years were down by

11.5 when using extended release pramipexole and 9.1 when using

immediate release pramipexole.

In both early and advanced Parkinson's Disease better efficacy was achieved when using the

extended release version of pramipexole. The adverse events were typical for dopaminergic

drugs.

©2014 Viartis